The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
CONCLUSION: This study analyzed the clinical characteristics and survival of patients with HR+/HER2+ breast cancer as a special subgroup. ERBB2, IKZF3, LASP1, and CDK12 were the potential markers of the resistance of endocrine therapy, and they will provide new strategies for clinicians.
PMID: 31209793 [PubMed - as supplied by publisher]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Chen K, Quan J, Yang J, Chen Z Tags: Clin Transl Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Endocrine Therapy | Epidemiology | Genetics | HER2 | Hormones | Study